首页> 美国卫生研究院文献>other >Retrospective Comparative Study of the Effects of Dendritic Cell Vaccine and Cytokine-Induced Killer Cell Immunotherapy with that of Chemotherapy Alone and in Combination for Colorectal Cancer
【2h】

Retrospective Comparative Study of the Effects of Dendritic Cell Vaccine and Cytokine-Induced Killer Cell Immunotherapy with that of Chemotherapy Alone and in Combination for Colorectal Cancer

机译:回顾性比较树突状细胞疫苗和细胞因子诱导的杀伤细胞免疫治疗与单独化疗和联合治疗结直肠癌的效果比较

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Purpose. This retrospective study determined the delayed-type hypersensitivity (DTH) skin test and safety of dendritic cell (DC) vaccine and cytokine-induced killer (CIK) cell immunotherapy and the survival compared to chemotherapy in 239 colorectal cancer (CRC) patients. Methods. DTH and safety of the immunotherapy were recorded. The overall survival (OS) and disease free survival curves were compared according to the immunotherapy and/or chemotherapy received with Kaplan-Meier estimates. Results. Of the 70 patients who received immunotherapy, 62.86% had a positive DTH skin test, 38.57% developed fever, 47.14% developed insomnia, 38.57% developed anorexia, 4.29% developed joint soreness, and 11.43% developed skin rash. For 204 resectable CRC patients, median survival time (MST) (198.00 days) was significantly longer in patients with immunotherapy plus chemotherapy than with chemotherapy alone (106.00 days) (P = 0.02). For 35 patients with unresectable or postsurgery relapsed CRC and who were confirmed to be dead, no statistical difference was observed in the MST between the patients treated with immunotherapy and with chemotherapy (P = 0.41). MST in the patients treated with chemotherapy plus immunotherapy was 154 days longer than that of patients treated with chemotherapy alone (P = 0.41). Conclusions. DC vaccination and CIK immunotherapy did not cause severe adverse effects, induce immune response against CRC, and prolong OS.
机译:目的。这项回顾性研究确定了迟发型超敏反应(DTH)皮肤测试以及树突状细胞(DC)疫苗和细胞因子诱导的杀伤性(CIK)细胞免疫疗法的安全性,以及与239名大肠癌(CRC)患者相比化疗的生存期。方法。记录DTH和免疫治疗的安全性。根据接受了Kaplan-Meier估计的免疫疗法和/或化疗,比较了总生存期(OS)和无病生存曲线。结果。在接受免疫治疗的70名患者中,DTH皮肤试验阳性率为62.86%,发烧为38.57%,失眠为47.14%,厌食症为38.57%,关节酸痛为4.29%,皮疹为11.43%。对于204例可切除的CRC患者,接受免疫治疗和化疗的患者的中位生存时间(MST)(198.00天)比单纯接受化疗的患者(106.00天)明显更长(P = 0.02)。对于35例无法切除或手术后复发的CRC并被证实已死亡的患者,免疫疗法和化学疗法之间的MST差异无统计学意义(P = 0.41)。化疗加免疫疗法的患者的MST比单纯化疗的患者长154天(P = 0.41)。结论。 DC疫苗接种和CIK免疫疗法不会引起严重的不良反应,不会引起针对CRC的免疫反应,并不会延长OS。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号